Business / Finance

RSS

American Scientific Resources now quoted on OTCQB market

American Scientific Resources, Inc. wishes to announces that it is now quoted on the OTCQB market.

24 Jan 2011

Hitachi Medical Systems America achieves top ranking among MRI vendors

In the 2010 Q4 User Satisfaction Survey, MD Buyline users have named Hitachi Medical Systems America (HMSA) the top rated MRI vendor. HMSA swept the top rankings in all six categories and earned a composite score 9.6 out of 10.

24 Jan 2011

Medisafe 1 Technologies' 2012 revenues to exceed $10M

Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company expects revenues in 2012 to exceed $10M .

24 Jan 2011

AnC Bio Holdings invests $4 million in Bioheart

Bioheart, Inc. announced today that it has entered into an agreement with AnC Bio Holdings, Inc., a South Korean biomedical company, and one of its U.S. agents for a $4 million equity investment. Bioheart has designated proceeds from the investment to advance the current clinical evaluation of its cell therapies for treating heart failure and related cardiac diseases.

24 Jan 2011

BDSI refutes MonoSol's patent infringement claims relating to BEMA Buprenorphine

BioDelivery Sciences International, Inc. today responded to a process patent infringement lawsuit filed and recently served against the Company and certain co-defendants by MonoSol Rx, LLC. The purpose in responding at this time is for BDSI to strongly refute MonoSol's claims and to assure BDSI stockholders that the Company remains focused on vigorously progressing its pipeline and not allowing this claim to present a distraction.

24 Jan 2011

Radiation Therapy Services to issue $50M of 9-7/8% Senior Subordinated Notes due 2017

Radiation Therapy Services Holdings, Inc.announced today that its wholly owned subsidiary, Radiation Therapy Services, Inc., has agreed to issue an aggregate principal amount of $50 million of 9-7/8% Senior Subordinated Notes due 2017.

24 Jan 2011

Novartis enters definitive merger agreement to acquire Genoptix

Genoptix, announced today that it has entered into a definitive merger agreement to be acquired by Novartis. Under the terms of the merger agreement, Novartis will commence an all cash tender offer for all outstanding shares of common stock of Genoptix at USD$25.00 per share.

24 Jan 2011

Teva Pharmaceutical announces entry into new three-year credit facility

Teva Pharmaceutical Industries Ltd. announced today that it has entered into a new three-year, $1.5 billion unsecured revolving credit facility, which replaces and expands existing credit lines at terms that are more favorable to Teva.

24 Jan 2011

CRI, Oncovir sign new investment agreement to produce immunological stimulant

Cancer Research Institute, a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund, a joint initiative with the Ludwig Institute for Cancer Research, has completed a new investment agreement with Oncovir, a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol- (Poly-ICLC).

24 Jan 2011

Novation, Lantheus Medical to distribute ABLAVAR and DEFINITY diagnostic imaging agents

Lantheus Medical Imaging, a worldwide leader in diagnostic medical imaging, today announced a national contract with Novation for ABLAVAR and DEFINITY Vial For Injectable Suspension, providing increased access to these important diagnostic imaging agents for health care providers served by Novation.

23 Jan 2011

CVAF completes new investment agreement with Oncovir for production of Hiltonol

Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund (CVAF), a joint initiative with the Ludwig Institute for Cancer Research (LICR), has completed a new investment agreement with Oncovir, Inc., a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol® (Poly-ICLC).

21 Jan 2011

Possible hospital merger in Mass. could accelerate trend toward consolidation

News outlets also report on another hospital merger as well as how a Minnesota psychiatric hospital gathered the necessary funds and support to be built.

21 Jan 2011

Pharmasset prices underwritten public offering of 3,300,000 shares of common stock

Pharmasset, Inc. announced today the pricing of an underwritten public offering of 3,300,000 shares of its common stock at an offering price of $46.33 per share. Of the shares being sold, Pharmasset is selling 2,300,000 shares and the selling stockholders are selling 1,000,000 shares. Pharmasset expects to receive net proceeds, after deducting the underwriting discount and estimated offering expenses, of approximately $101.5 million.

21 Jan 2011

Watson predicts $4.2 billion in revenues from Global Generics and Global Brand businesses

During an investor meeting held today in New York, NY, Watson Pharmaceuticals, Inc. provided an update on its Global businesses, including a detailed overview of its commercial operations and pipeline developments within its Global Generics and Global Brands businesses, and an update of achievements within its Global Operations. In conjunction with the meeting, the Company provided its preliminary 2011 financial and long term growth forecasts.

21 Jan 2011

Jiangbo Pharmaceuticals reaches settlement with debenture holders

Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has reached a settlement with the holder of its November 2007 Debenture and with the holders of its May 2008 Notes under which the Company has agreed to issue to such holders a total of 886,277 shares of its common stock as a payment for all delinquent interest and associated penalties with respect to its November 2007 Debenture and May 2008 Notes.

21 Jan 2011

SQI fourth quarter net loss increases to $2,621,000

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced its financial and operational results for the fourth quarter and year ended September 30, 2010.

21 Jan 2011

Intellipharmaceutics receives purchase agreement commitments for $12,000,000

Intellipharmaceutics International Inc. today announced that it has received purchase agreement commitments from institutional investors to provide the Company with approximately US$12,000,000 in gross proceeds through the sale of its common stock and warrants.

21 Jan 2011

Surgery Partners to acquire NovaMed for $214 million

NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of Surgery Center Holdings, Inc. ("Surgery Partners") in a transaction valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.

21 Jan 2011

inVentiv Health to acquire Campbell Alliance and i3

inVentiv Health, Inc., a leading provider of outsourced clinical development, launch and commercialization services to the global healthcare industry, today announced that it has signed a definitive agreement to acquire Campbell Alliance, a leading management consulting firm specializing in serving the pharmaceutical and biotech industries. Yesterday, inVentiv announced that it has signed a definitive agreement to purchase i3 from Ingenix.

From Thermo Fisher Scientific Inc. 21 Jan 2011

WSJ: Insurers' profits on the rise

Health insurers' fourth-quarter reports will provide an early glimpse into how much wind the health overhaul could take out of plans' profits—and, so far, Wall Street estimates don't look all that bad for the industry (Johnson, 1/20).

21 Jan 2011